Three companies — Abiomed Inc., Elixir Medical Inc. and ImThera Medical Inc. — are touting the results of clinical trials:
- Results from the U.S. registry of Abiomed Inc. (NSDQ:ABMD) AB5000 patients were recently published in the September 2010 issue of TheAnnals of Thoracic Surgery. The paper, “Use of the AB5000TM Ventricular Assist Device in Cardiogenic Shock After Acute Myocardial Infarction (AMI),” concludes that the “results from this nationwide registry suggest that VADs can restore normal hemodynamics and support recovery of native cardiac function in the majority of survivors when conventional therapies fail.”
- Elixir Medical Corp. announced the initiation of patient enrollment in the EXCELLA BD Randomized Clinical Trial of its Novolimus Eluting Coronary Stent System (CSS) with bioabsorbable coating, the Elixir DESyne BD Novolimus Eluting CSS. The first cases were enrolled by Professor Joachim Schofer from the Universitäres Herz-und Gefäβzentrum in Hamburg, Germany and Dr. Karl E. Hauptmann from the Krankenhaus der Barmherzigen Brüder in Trier, Germany.
- ImThera Medical Inc. announced interim results from its OSA European clinical study of 10 patients who were surgically implanted with ImThera’s aura6000 hypoglossal nerve neurostimulation device for treating Obstructive Sleep Apnea (OSA). The target population for ImThera’s neurostimulation device is moderate and severe OSA patients who are non-compliant with or cannot tolerate Continuous Positive Airway Pressure (CPAP).